RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Oronsky B, Scicinski J, Reid T, Oronsky A, Carter C, Oronsky N, Cabrales P.Discov Med. 2016 Apr;21(116):251-65.PMID: 27232511

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C.Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016.PMID: 27330954 Free PMC article.

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Fens MH, Cabrales P, Scicinski J, Larkin SK, Suh JH, Kuypers FA, Oronsky N, Lybeck M, Oronsky A, Oronsky B.Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. Epub 2016 Jul 4.PMID: 27377482

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C.Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.PMID: 27403127 Free PMC article.

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.

by kira@rippkedesign.com | Nov 1, 2021 | Data Papers, Journal Publications

Oronsky B, Carter C, Scicinska A, Oronsky A, Oronsky N, Lybeck M, Scicinski J. Oncotarget. 2016 Feb 23;7(8):9041-5. doi: 10.18632/oncotarget.6984. PMID: 26814434; PMCID: PMC4891024.